Enanta Pharma (ENTA) Tops Q1 EPS by 10c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019
February 6, 2020 4:00 PM ESTWebcast and Conference Call Today at 4:30 p.m. ET
Positive results from part 1 of the Phase 1a/b clinical study of EDP-514 in healthy subjects- Part 2 initiated in nuc-suppressed chronic hepatitis B virus patients Research and development programs progressing well -- several milestones expected in 2020 from our RSV, NASH, and HBV programs Royalty revenue for the quarter was $52.6 million Cash and marketable securities totaled $414.7 million at December 31, 2019
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:... More
